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Summary
Objective: Progression of joint damage in osteoarthritis (OA) is likely to result from an imbalance between cartilage degradation and synthesis
processes. Markers reﬂecting these two components appear to be promising in predicting the rate of OA progression. Both N- and C-terminal
propeptides of type II collagen reﬂect the rates of collagen type II synthesis. The ability to quantify the procollagen peptides in biological ﬂuids
would enable a better understanding of OA disease pathology and provide means for assessing the proof of mechanism of anabolic disease
modifying OA drugs (DMOADs).
Methods: A polyclonal antibody that recognizes the sequence GPKGQKGEPGDIKDI in the propeptide region of rat, dog, and human type II
collagen was raised in chicken and peptide-afﬁnity puriﬁed. The immunoafﬁnity liquid chromatography mass spectrometry (LC-MS/MS) was
used to extensively characterize N-terminal procollagen type II (NPII) peptides found in biological ﬂuids. The novel competition enzyme-linked
immunosorbent assay (ELISA) assay was developed to quantitatively measure the NPII peptides.
Results: Several peptides ranging from 17 to 41 amino acids with various modiﬁcations including hydroxylations on proline and lysine resi-
dues, oxidation of lysines to allysines, and attachments of glucose and galactose moieties to hydroxylysines were identiﬁed in a simple system
such as ex vivo cultures of human articular cartilage (HAC) explants as well as in more complex biological ﬂuids such as human urine and
plasma. A competitive ELISA assay has been developed and applied to urine, plasma, and synovial ﬂuid matrices in human, rat and dog
samples.
Conclusion: A novel NPII assay has been developed and applied to OA and normal human subjects to understand the changes in collagen
type II synthesis related to the pathology of OA.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Key words: Biomarkers, Procollagen type II.Articular cartilage has an important role in cushioning the
joints in the skeleton. It is composed mainly of type II colla-
gen and various proteoglycans including aggrecan. When
type II collagen is synthesized by chondrocytes, the imma-
ture protein contains three extra domains: a signal peptide
and N- and C-terminal propeptide domains. The signal
sequence directs the protein to be secreted, whereas pro-
peptide regions upon cleavage allow mature collagen mol-
ecules to be incorporated into the extracellular matrix. As
these N- and C-terminal propeptides are released only dur-
ing synthesis of the new molecules, their production is
known to reﬂect the rate of type II collagen synthesis1. As
these propeptides span from 87 to 245 amino acids for N-
and C- terminal regions, respectively, there are several
immunoassays to measure them depending on the epitope
that was used to generate the antibody.
A homeostatic balance between matrix synthesis and
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1494joint diseases such as osteoarthritis (OA) and rheumatoid
arthritis (RA), resulting in a net increase in catabolism of
matrix molecules, especially proteoglycans2,3 and collagen
type II4,5, and eventually in loss of joint function.
Recently it has been discovered that in the early stages of
OA, chondrocytes proliferate and synthesize more collagen
molecules presumably to compensate for the loss of colla-
gen type II due to the increased proteolytic activities.
Synthesis of new type II collagen has been shown to be
increased in OA patients as evaluated by the CPII assay
that quantiﬁes a C-terminal propeptide region within collagen
type II molecule6e10. Another collagen synthesis biomarker,
which is speciﬁc to the embryonic form of procollagen type II,
was ﬁrst identiﬁed by Aigner et al. and found to be synthe-
sized by chondroprogenitor cells in developing tissues11. It
is characterized by the presence of an extra cysteine-rich
region in the N-terminus propeptide of type II collagen and
termed PIIANP. Healthy adults do not appear to express
PIIANP11, but adults suffering from OA have been shown
to re-express it. Rousseau et al.12 developed an enzyme-
linked immunosorbent assay (ELISA) assay using anti-
bodies to type IIA procollagen amino terminal propeptide
and showed that PIIANP is decreased in the plasma of
knee OA and RA patients. Garnero et al.13 proposed that
disequilibrium between synthesis of collagen type II, as
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articular cartilage, as measured by the levels of C-terminal
telopeptides (CTX-II), represents a predictive marker of
OA disease progression and severity. Patients who
exhibited a greater degree of disease progression as deter-
mined by radiography had lower levels of PIIANP and
higher levels of CTX-II. The combined analysis of these
two biomarkers as the ‘‘uncoupling index’’ of cartilage
turnover was more effective in predicting 1-year radiological
progression in knee OA than the measurement of each sin-
gle marker. However, the recent paper by Sharif et al.14
shows that OA patients with serum levels of PIIANP in the
highest quartile had a signiﬁcantly higher risk of disease
progression. As PIIANP data in OA progression studies is
not always consistent, further understanding of the PIIANP
data is needed before it can be fully utilized as a biomarker
of anabolic activity. More recently, an assay for the adult
type II collagen N-propeptide (PIINP) has been developed15.
This PIINP biomarker, which recognizes the N-terminal
region spanning from amino acid 30 to 43, demonstrated
a decreased anabolic activity in RA subjects suggesting
that not only PIIANP, but also PIINP might be regulated in
OA disease11e15.
Several markers that reﬂect collagen matrix degradation
have been reported in the literature including the C-terminal
telopeptides16e18, collagen type II neoepitope peptides such
as TIINE19,20, C2C4,5, and HELIX peptides21 with some of
them such as CTX-II being extensively characterized. How-
ever, markers that reﬂect the synthesis of collagen type II
and its adult form, in particular including CPII and PIINP,
are not characterized to the same extent. Speciﬁcally, the
N-terminal collagen type II peptides are not well character-
ized in biological ﬂuids. As several post-translational modiﬁ-
cations (PTMs) of the propeptide region are known, it is
unclear whether a published PIINP assay detects all PIINP
peptides or only unmodiﬁed portion that binds to the anti-
body that was raised using unmodiﬁed sequence. Moreover,
the N-terminal propeptide region is known to be processed
by several enzymes including matrix metalloproteinases
(MMPs)22 resulting in potentially shorter fragments that
may not be detected by the PIINP assay that utilizes an
antibody generated by Olsen et al.15 to the region starting
only at position 29 from the N-terminus.
Using the adult form of procollagen type II as a biomarker
of type II collagen synthesis will enable development of dis-
ease modifying OA drug (DMOAD) anabolic therapies. As
there are numbers of regulatory factors and anabolic medi-
ators, e.g., osteogenic protein 1 (OP-1), which may have
therapeutic potential as anabolic DMOADs, there is
a need for biomarkers capable of measuring matrix synthe-
sis that would facilitate testing proof of mechanism of these
drugs in clinic.
This paper presents a description of the methods used for
the identiﬁcation and characterization of the N-terminal pro-
collagen type II (NPII) peptides from various biological ﬂuids
including urine and plasma as well as simple ex vivo system
of human articular cartilage (HAC) explants. The sequences
of speciﬁc peptides that result from processing of the NPII
which are secreted into systemic bioﬂuids as well as PTMs
of these peptides are described. Moreover, this paper
describes the development and application of the ELISA to
measure both modiﬁed and unmodiﬁed peptides as well as
peptides of varying length starting from theN-terminus in var-
ious biological ﬂuids. An application of the NPII biomarker to
cross-sectional human OA and non-OA (control subjects)
samples provided a preliminary indication of decreased adult
collagen type II synthesis in subjects with symptomatic OA.Materials and methodsPEPTIDES FOR ANTIBODY GENERATIONThe NPII standard peptide sequence CZ-GPKGQKGEPGDIKDI, where Z
represents a proprietary to Aves Labs, Inc. (Tigard, OR, USA) linker was
synthesized by Aves. Biotin-GPKGQKGEPGDIKDI was synthesized in
house using solid-phase peptide synthesis technology. Mass spectroscopy
and quantitative HPLC (high performance liquid chromatography) were per-
formed on all peptides to conﬁrm the purity and ﬁdelity of these peptides.ANTIBODY PRODUCTION AND PURIFICATIONPolyclonal antibody production was completed by Aves Labs, Inc. (Tigard,
OR, USA). Two hens were immunized with keyhole limpet hemocyanin
(KLH) conjugated to the standard peptide. After a total of four injections,
immune eggs were collected and following a lipid extraction, the IgY fraction
was peptide-afﬁnity puriﬁed from the yolks. Egg yolks contained approximately
25 mg of IgY per ml.EX VIVO INDUCTION OF CARTILAGE DEGRADATIONArticular cartilage was dissected from a knee obtained from a patient
undergoing knee replacement (65-year-old female). Visually normal (i.e.,
not ﬁbrillated) cartilage was cut into small pieces (w2 mm) and cultured in
96-well plates with 200 ml of dulbecco/vogt modiﬁed eagle’s minimal essential
medium (DMEM) media (Gibco BRL high glucose, 25 mM Hepes, containing
2 mM L-glutamine and 1 mM sodium pyruvate) freshly supplemented with 1
hybridoma lymphocytes-1 (HL-1) (Bio Whitaker) and 5 mg/ml ascorbic acid
(Sigma), containing 0.1 ng/ml interleukin (IL)-1b (R&D)þ 50 mg/ml oncostatin
M (R&D) or vehicle as described in Ref. 4. Media was replaced every 3e5
days and cartilage was cultured for a total of 22 days. Supernatants at day
3were frozen and stored at70Cprior to LC-MS/MS analysis for procollagen
type II peptides.IMMUNOAFFINITY COLUMN PREPARATIONOn-line immobilized antibody (immunoafﬁnity) columns were prepared as
described in Ref. 17. Brieﬂy, the antibody was immobilized onto a Poros
Epoxide immunodetection cartridge (Applied Biosystems, Framingham,
MA, USA). The cartridge was equilibrated with 0.5 M Na2SO4, 0.1 M sodium
phosphate (pH 8.8) at 1 ml/min. The 1.5 M Na2SO4, 0.1 M sodium phosphate
solution was added until the A280 was less than 10% of the maximum A280
and re-circulated for another 30 min. The column was then removed and
incubated at room temperature for 24e72 h. After incubation, the remaining
epoxide sites were blocked with 0.2 M Tris base (pH 10.5) at room temper-
ature for 2 h.PEPTIDE IDENTIFICATION BY LC-MS/MSSamples were analyzed on a quadrupole time-of-ﬂight (Q-TOF) mass
spectrometer (Waters, Beverly, MA, USA) coupled to a CapLC (Waters, Mil-
ford, MA, USA) system equipped with an autosampler, gradient and auxiliary
pump. The peptides were separated on a Pepmap column (75 mm 150 mm,
3 mm particle) (LC Packings, San Francisco, CA, USA) prior to introduction
into the mass spectrometer. Separation was achieved using a 50 min linear
gradient of 95% H2O, 0.1% HCOOH to 95% MeCN, 0.1% HCOOH.
Data dependent MS/MS experiments were performed using a modiﬁed
nanospray source designed to hold a distally coated picotip (360 mm
OD 20 mm ID 10 mm tip diameter) (New Objective, Cambridge, MA,
USA). The data was processed by ProteinLynx version 3.5 (Waters, Beverly,
MA, USA) to generate searchable.pkl ﬁles. The data was searched against
NCBI database with no enzyme speciﬁcity to identify endogenously pro-
duced peptides. Several variable modiﬁcations including methionine
oxidation and proline or lysine hydroxylation were added to the search
parameters. All identiﬁcations of peptides exceeded the signiﬁcant homology
threshold with some identiﬁcations exceeding identity threshold.ELISA PROCEDURENunc 96-well ﬂat-bottom MaxiSorp microtiter ELISA plates (Nalge Nunc
International, Roskilde, Denmark) were pre-coated with peptide-afﬁnity puri-
ﬁed IgY (2 mg/ml) in 0.1 N NaHCO3 buffer pH 8.2 for 18 h at room temperature
and 100% humidity. Unbound antibody was removed and the un-reactive
sites on the plates were blocked with blocking buffer (3% protease-free bovine
serum albumin (BSA), 0.05%Tween-20, 0.02% thimerosal, added to dulbecco’s
phosphate-buffered saline (DPBS) with pH adjusted to 7.4) for 1 h, 37C and
100% humidity, followed by three washes with 0.05% Tween-20 in normal sa-
line. NPII standard was prepared in triplicates by diluting a 1 mg/ml stock
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0.02% thimerosal, added to DPBS, pH adjusted to 7.4) at six concentrations:
128 ng/ml, 32 ng/ml, 8 ng/ml, 2 ng/ml, 0.5 ng/ml and 0.125 ng/ml ﬁnal con-
centration. This was accomplished by making a 2 upper standard at
256 ng/ml and performing 1:4 serial dilutions in the assay plates. Biotin-la-
beled standard was prepared at a 2 concentration of 1 ng/ml by diluting
a 1 mg/ml stock of biotinepeptide in ELISA assay buffer. Total assay volume
equaled 150 ml/well. For maximum binding (Bo) control, three wells received
biotin label without standard. Biotinylated NPII peptide was allowed to com-
pete with standard peptide or unknown samples for 2 h at room temperature.
Unbound NPII is removed and biotinylated peptide is detected with horserad-
ish peroxidase (HRP) conjugated anti-biotin and developed using tetrame-
thylbenzidine (TMB) substrate. The absorbance of the resultant blue color
was read at 650 nm and was inversely proportional to bound NPII concentra-
tion in the sample.SAMPLESUrine and plasma samples were collected from men and women over 55
years of age in polypropylene tubes, aliquoted, and stored at 70C until
sample analysis. Typically, 100 ml of urine was aliquoted separately for mea-
surement of creatinine. All subjects were identiﬁed for the presence of joint
pain and radiographic signs of OA (KL 1). Two groups of subjects were
determined including symptomatic OA patients with radiographic OA of the
hip(s) and/or knee(s) (n¼ 66) and asymptomatic subjects with either radio-
graphic OA of the hand(s)/spine (n¼ 17) (i.e., cervical and lower lumbar)
or no radiographic signs of OA (non-OA) in the knee(s)/hip(s)/hand(s)/spine
(n¼ 12). The latter group is referred to as a reference control group.ResultsNPII ANTIBODY CHARACTERIZATIONThe collagen type II molecule contains two propeptide
regions: N- and C-terminal. The N-terminal region of colla-
gen type II is 87 amino acids long and contains GXP or
GXK motifs, whereas the C-terminal propeptide region
spans 245 amino acids and does not contain GXP/GXK
motifs (Table I). The 15-amino acid region GPKGQKGEPG-
DIKDI in the N-terminal propeptide region (Table I, under-
lined sequence) was selected for polyclonal antibody
generation. This sequence is unique to collagen type II
and conserved among human and most widely used pre-
clinical species such as rat and dog. Polyclonal antibodies
that recognize GPKGQKGEPGDIKDI were developed in
chicken and afﬁnity puriﬁed using a standard peptide. On-
line immobilization of the NPII antibody onto porous support
using epoxide chemistry resulted in a high capacity immu-
noafﬁnity column that was used to pull-down NPII peptides
from various ﬂuids.IDENTIFICATION AND CHARACTERIZATION OF NPII PEPTIDESHAC explants after 3 days of stimulation with IL-1b and
oncostatin M were used for the identiﬁcation of the NPII
peptides. In addition, urine and plasma from adult human
subjects were used to identify NPII peptides. For this,
50 ml of HAC supernatant, 0.3 ml of human plasma, and
1 ml of human urine were passed through NPII antibody
column and eluted with low pH solvent to disrupt antibo-
dyeantigen interactions. Several peptides of various
lengths were detected in the HAC supernatants, human
plasma and urine (Table II). An example of LC-MS spectra
of QDVRQPGPKGQKGEPGDIKD peptide that was
observed in all three samples is shown in the Fig. 1(AeC).Table
Sequence of human pr
QDVRQPGPKGQKGEPGDIKDI*VGPKGPPGPQGPAGEQGPRGDRGDK
*Underlined sequence was used to raise an antibody.Both triply and quadruply charged ions of the peptide
with various modiﬁcations have been observed. The
difference between major peaks was 40.5 and 54 m/z
for quadruply and triply charged ions, respectively, corre-
sponding to the series of 162 Da differences in molecular
weight (MW) of the peptide. This difference was attributed
to the sugar moiety attached to the peptide sequence and
based on the unique mass of 162 was ascribed to be
a hexose. Up to four hexose moieties within the peptide
sequence were observed. Moreover, for many of the
detected peptides, shifts in 4.0 and 5.3 m/z for quadruple
and triple charge states, respectively, were detected.
These shifts resulted in a 16 Da increase in the MW of
the peptide which for the collagen molecule has been
known to be due to hydroxylation of either proline and
lysine residues.
As a result of the immunoafﬁnity pull-down experiments
several peptides that varied in length, hydroxylation and
sugar attachment patterns were identiﬁed (Table II). All
identiﬁed peptides contained the N-terminal sequence cor-
responding to the beginning of the N-terminus, whereas
their C-terminal ends varied depending on the processing
site. The C-terminal ends of two major peptides had an
aspartic acid at positions 17 and 20 from the N-terminus,
respectively. These two cleavages after the aspartic acid
residue are reported to be initiated by the members of the
MMP enzyme family20. Additional C-terminal processing
sites included the lysine residue at position 19, glycine res-
idues at positions 34 and 40, and the proline residue at po-
sition 29. Each peptide was found to be present with one,
two or up to three hydroxylations and up to four glycosyla-
tion states. Furthermore, upon detailed investigation of the
LC-MS spectrum of the QDVRQPGPKGQKGEPGDIKD
peptide it was found that its calculated MW was one mass
unit less than theoretical. Utilizing LC-MS/MS capabilities,
we found that a modiﬁcation on the lysine residue arising
from the oxidation of the side chain producing allysine
was contributing to the decrease in the MW of the peptide
by one. Manual interpretation of the MS/MS spectrum of
QDVRQPGPKGQKGEPGDIKD provided evidence that
the lysine residue at the ninth position from the N-terminus
was modiﬁed to allysine [Fig. 1(D)]. The difference between
singly charged product ions at m/z 1005.52 and 877.4 re-
sulted in the loss of 128 from the QDVRQPGP (aK), where
aK stands for allysine, ion that corresponded to the loss of
allysine. Moreover, digestion of the immunoafﬁnity isolated
peptide from the human urine with LysC enzyme resulted
in cleavages only after lysine residues in positions 19 and
24 from the N-terminus, whereas no cleavages were ob-
served after lysine residues in positions 9 and 12. This sug-
gests that both lysines in 9 and 12 positions are modiﬁed
and resistant to the enzymatic digestion (Table II). This ﬁnd-
ing is consistent with literature reports suggesting that hy-
droxylysines are typically further modiﬁed by O-linked
glycosylation to give ((Glca1e2)Galb1-O-Lys)23.NPII ELISA ASSAY DEVELOPMENTA novel competition ELISA for detection of human procolla-
gen (NPII)wasdeveloped. Theassay is basedoncompetitionI
ocollagen type II
GEKGAPGPRGRDGEPGTLGNPGPPGPPGPPGPPGLGGNFAA
Table II
Peptides and their PTMs identified in HAC, human urine, and plasma using NPII antibody
QDVRQPGPKGQKGEPGD 1e2OH/1e4 Hex*
QDVRQPGPKGQKGEPGDIK 1e2OH/1e4 Hex
QDVRQPGPKGQKGEPGDIKD 2e3OH/1e4 Hex*
QDVRQPGPKGQKGEPGDIKDIVGPKGPPGP 2OH/1e4 Hex
QDVRQPGPKGQKGEPGDIKDIVGPKGPPGPQGPAG 2OH/1e4 Hex
QDVRQPGPKGQKGEPGDIKDIVGPKGPPGPQGPAGEQGPRG 2OH/1e4 Hex
*The most abundant peptides.
1497Osteoarthritis and Cartilage Vol. 16, No. 12of standard or sampleNPII with biotin-labeledNPII peptide for
IgY (chicken anti-NPII peptide) coated on a 96-well microtiter
plate. Standard peptide CZ-GPKGQKGEPGDIKDI used in
the ELISA assay contains an amino acid sequence that has
been identiﬁed to be a part of the most abundant peptides
identiﬁed-by LC-MS. The concentrations of standard, label
and sample dilutions were predetermined by checkerboard500 550 700 750600 650
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Fig. 1. LC-MS spectra of the NPII fragments. Each spectrum represents on
(RP-HPLC) obtained by immunoafﬁnity pull-down of the procollagen II pe
charge states for various forms of the QDVRQPGPKGQKGEPGDIKD pep
spectrum of the QDVRQPGP(aK)GQ(HyK)GEPGDIKD with three Hex mo
terminal fragment ions were observed allowing for manual sequence idenELISA and diluted in 0.1% BSAePBST, pH 7.4. To establish
a standard curve, NPII peptide was diluted fourfold in a con-
centration range between 0.125 and 128 ng/ml. Following
an incubation period of 2 h at 37C, plates were washed
four times and incubated for 1 h with 150 ml/well HRP anti-bi-
otin which was diluted 1:10,000 in PBST. The color reaction
was developed by adding 150 ml/well peroxidase substrate800 850 900 950 1000 m/z
1: TOF MS ES+
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e peak in the reverse phase-high performance liquid chromatogram
ptides from (A) HAC, (B) plasma, and (C) urine samples. Different
tide with up to four hexose moieties were detected. (D) An MS/MS
ieties, m/z 884.03 for the triple charged parent ion. Both N- and C-
tiﬁcation. In addition, a facile loss of sugar moieties was observed.
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run of the assay included data for a single standard curve
across a range of concentrations, in duplicate.
Intra-assay precision was determined by testing three
replicates of twofold dilutions (seven total dilutions) of a pos-
itive control (NPII peptide spiked into human plasma or
urine) on the same day. The results for each assay are
reported as percent coefﬁcient of variations (CVs) of the
endpoint titer and the range for all dilution points are also
reported in the table below (Table III).
For the NPII ELISA, the limit of detection (LOD) was
established to be 0.1 ng/ml. The lower limit of quantiﬁcation
(LLOQ) is the lowest amount of NPII peptide in a sample
that can be quantitatively determined with suitable precision
and accuracy. The LLOQ for the NPII ELISA was 0.5 ng/ml
in either human plasma or urine. The upper limit of quanti-
ﬁcation (ULOQ) was 128 ng/ml.APPLICATIONS OF THE NPII ASSAYThe NPII ELISA assay was utilized to measure the levels
of the NPII peptides in various bioﬂuids and to understand
its variability in various species and feasibility for future ap-
plications. The basal levels for plasma and urine were mea-
sured in healthy human, dog, and rat subjects (Table III). In
all three species, the levels in urine were higher than in
plasma approximately two-fold to three-fold. NPII was also
detected in synovial ﬂuid lavage (about 10-fold diluted
with PBS) at 257.7 71.2 ng/ml.Table III
Summary of NPII assay validation results and levels of NPII
peptides detected in the urine, plasma or synovial fluid of healthy
human, dog, and rat subjects*
Analyte NPII peptide NPII peptide
Species Human Human
Matrix Plasma Urine
MRD* 1:16 ﬁnal 1:16 ﬁnal
Sample volume, ml 75 75
Method type Competition ELISA Competition ELISA
Linearity Four orders
of magnitude
Four orders
of magnitude
Sensitivity
(LOD)*, ng/ml
w0.1 w0.1
Sensitivity
(LLOQ), ng/ml
0.5 0.5
Range
(ULOQ), ng/ml
128 128
Intra-assay
precision
(%CV*), (n¼ 3)
0.5e9 3e11
Mean % recovery 95.30 108.80*
Species n Fluid NPII (ng/ml)
(meanSD)
Human 29 Plasma 17.45 8.95
6 Urine 36.8 33.2
Dog 20 Plasma 4.14 5.53
4 Urine 9.43 6.59
Rat 2 Plasma 40.2þ 4.3
8 Urine 125.3 24.5
Human reference control subjects were 55e70 years old males
and females. Dogs were mixed-breed of gray labs with hounds
and ranged in weight from 20 to 30 kg. Rats were 180e200 g Lewis
male rats.
*MRD - minimum required dilution; LOD - lower limit of detection;
CV - coefﬁcient of variation.The assay was subsequently used to evaluate the differ-
ence in levels of the NPII biomarker between age and sex
matched reference non-OA subjects and patients with
both conﬁrmed radiographic OA in the hip(s) and/or knee(s)
and symptomatic disease. The mean value for plasma NPII
in the reference control group was 17.45 ng/ml (n¼ 29),
whereas the mean value for the symptomatic OA group
was 3.25 ng/ml (n¼ 22). An almost ﬁvefold decrease in
the NPII levels in the symptomatic OA group was detected.
The mean NPII levels in the symptomatic OA group were
statistically signiﬁcant lower as compared to the mean
NPII values in the reference controls (P< 0.0001) (Fig. 2).Discussion
Imbalance between degradative and reparative pro-
cesses characterized by loss of cartilage matrix molecules
and their synthesis has been implicated in OA. Develop-
ment of biomarkers that will allow the quantitative measure-
ment of the net loss of cartilage by assessing both rate of
cartilage degradation and synthesis will tremendously aid
the understanding of OA disease pathology.
In this report, we describe the development of a polyclonal
antibody that recognizes the N-terminal propeptides from
amino acid in position 7 to 21. This antibody was used to
immunoafﬁnity capture and enrich for peptides from HAC,
urine and plasma, thus making the process of peptide iden-
tiﬁcation feasible.
Several peptides from the N-terminal region of collagen
type II were identiﬁed. None of the peptides contained a cys-
teine-rich region as described by Sandell to be characteris-
tic of the embryonic type IIA form of type II collagen. All of
the peptides matched sequences reported to be derived
from the adult procollagen type II even though the se-
quence used to generate the antibody is also found in the
embryonic procollagen type IIA form. These ﬁndings sug-
gest that embryonic form was not abundant in healthy refer-
ence control subjects or was too long to be detected by the
mass spectrometry (MS) technology. We did not attempt toReference Control OA
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Fig. 2. Cross-sectional evaluation of the NPII levels in the plasma of
reference control and OA patients. Statistically signiﬁcant
(***P< 0.0001) difference was observed between symptomatic
OA patients with radiographic OA in the hip(s) and/or knee(s) and
a reference control group consisting of healthy volunteers without
symptoms and radiographic OA in the hip(s) and/or knee(s); a sub-
set of the ﬁrst group (n¼ 17) was presented with radiographic OA in
the smaller joints such as hand(s) and/or spine.
1499Osteoarthritis and Cartilage Vol. 16, No. 12isolate peptides from the OA subjects. Moreover, all identi-
ﬁed peptides contained the N-terminus starting with resi-
dues QDVR. that corresponds to the beginning of the N-
terminal region of procollagen type II. However, the C-ter-
mini of the peptides were different. Among several identiﬁed
peptides only two peptides have at least partial epitope that
would have been recognized by the PIINP antibody. This
suggests that the pool of peptides that the NPII assay mea-
sures is different than that of PIINP. All identiﬁed peptides
were heavily modiﬁed by hydroxylations at proline and ly-
sine residues as well as glycosylated by glucose and galac-
tose at hydroxylysine residues. The lysine residue at
position 9 was also identiﬁed to be modiﬁed to allysine res-
idue by the oxidation of the side chain amino group to
aldehyde moiety. It is important to note that even though an-
tibody was generated to the sequence of type II collagen
propeptide only, it was found to bind both unmodiﬁed and
post-translationally modiﬁed peptides. This suggests that
our antibody recognizes all of the expected peptides regard-
less of the modiﬁcation and not just a small subset of them.
For the development of the quantitative assay, two con-
siderations were given: LC-MS/MS and ELISA assays. An
LC-MS/MS assay typically is developed for a single most
abundant peptide representing the region of the molecule,
whereas an ELISA assay measures all peptides that have
immunoreactivity to the peptide sequence allowing for the
quantiﬁcation of the total signal coming from the region of
the molecule. Resulting from our experience of developing
a quantitative immunoafﬁnity LC-MS/MS assay to measure
collagen type II 45-mer peptide17, we considered applying
a similar approach for the measurement of the most abun-
dant NPII peptide utilizing a unique combination of the
immuno-afﬁnity and LC-MS/MS technology. However, due
to the complexity of identiﬁed peptides and difﬁculties mak-
ing synthetic standards with hydroxylysine, allysine and
complex sugar moieties, no attempts were made to develop
an LC-MS/MS assay. For the quantiﬁcation of the N-termi-
nal collagen type II peptides, a competitive ELISA assay
was chosen as it will provide a means of detecting all of
the various forms of NPII peptides. This technique is based
on immunological detection and quantitation of a single or
multiple molecular species in biological samples. To
achieve robust assay performance, key assay parameters
such as reagent concentrations, volumes, dilution factors,
assay incubation times, and temperatures were optimized.
Among many key assay parameters, establishing the
most optimum dilution factor at which no matrix interfer-
ences are observed while still measuring a robust signal
was the most challenging step. We found that it was neces-
sary to dilute both urine and plasma samples 16-fold to min-
imize matrix interference with analyte recovery ranging from
95 to 109%. In addition, intra-assay precision as measured
by the %CV has been established to be less than 15% for
both plasma and urinary assays.
Basal levels of NPII were measured in urine and plasma
samples from human subjects and other preclinical species
such as rat and dog. A common trend showing higher levels
of the NPII in urine as compared to plasma was observed
across all species (2e3 fold). This suggests that the small,
polar NPII peptides concentrate in urine once cleared
through the glomerulus. The NPII peptides were also
detected in the synovial ﬂuid lavage, at least in rat samples,
as other species synovial ﬂuid samples were not available
at the time of testing. The ability to apply the same assay
to measure NPII peptides across many species including
human subjects allows for the translation of the NPII bio-
marker from preclinical to clinical studies.Inter-subject variability for NPII was evaluated and shown
to be greater than 50% CV for 29 reference control subjects.
This indicates that clinical studies using NPII as biomarker
will have to be appropriately powered with enough subjects
to achieve statistical signiﬁcance. Utilizing the NPII assay to
analyze cross-sectional human OA and non-OA reference
control samples demonstrated a signiﬁcant difference in
plasma NPII levels between reference control subjects
and patients exhibiting both symptoms and structural
changes of OA. A comparable difference between PIINP
levels in healthy controls and RA subjects was reported
by Olsen et al.15 suggesting that decreased circulating
levels of the NPII peptides are consistent with reduced
anabolic activity of the articular cartilage in various joint dis-
eases such as RA and symptomatic OA.Conﬂict of interest
There are no real or potential conﬂicts of interest.References
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